IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.97B
1-Year Est. Return
106.57%
This Fund
S&P 500
1 Year Est. Return
+106.57%
AUM
$1.97B
AUM Growth
+$601M
(+44%)
Holding
97
Top Buys
| 1 | +$52.5M | |
| 2 | +$51M | |
| 3 | +$45.3M | |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$37.4M |
| 5 |
DexCom
DXCM
|
+$32.3M |
Top Sells
| 1 | +$63.9M | |
| 2 | +$40.4M | |
| 3 | +$30.1M | |
| 4 |
BrightSpring Health Services
BTSG
|
+$13.4M |
| 5 |
Pfizer
PFE
|
+$12.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$31B
| $218M | 11.03% |
1,250,000
-350,000
|
|
||
2
Revolution Medicines
RVMD
$19.6B
| $95.6M | 4.84% |
1,200,000
+800,000
|
|
||
3
Vera Therapeutics
VERA
$2.87B
| $91.2M | 4.62% |
1,800,000
+100,000
|
|
||
4
Cytokinetics
CYTK
$7.85B
| $89M | 4.51% |
1,400,000
|
|
||
|
5
Regeneron Pharmaceuticals
REGN
$81.6B
| $81M | 4.11% |
105,000
+55,000
|
|
||
6
Medtronic
MDT
$115B
| $64.8M | 3.29% |
675,000
+525,000
|
|
||
7
Intuitive Surgical
ISRG
$173B
| $62.3M | 3.16% |
110,000
+85,000
|
|
||
8
Rhythm Pharmaceuticals
RYTM
$6.35B
| $50.8M | 2.58% |
475,000
+255,000
|
|
||
9
Alignment Healthcare
ALHC
$3.7B
| $43.5M | 2.2% |
2,200,000
+600,000
|
|
||
10
Cardinal Health
CAH
$51.1B
| $41.1M | 2.08% |
200,000
+70,000
|
|
||
11
CVS Health
CVS
$97.1B
| $39.7M | 2.01% |
500,000
+300,000
|
|
||
12
Edgewise Therapeutics
EWTX
$3.14B
| $37.2M | 1.89% |
1,500,000
|
|
||
13
Glaukos
GKOS
$5.99B
| $36.7M | 1.86% |
325,000
+225,000
|
|
||
14
Novartis
NVS
$308B
| $34.5M | 1.75% |
250,000
+50,000
|
|
||
|
15
DexCom
DXCM
$26.1B
| $33.2M | 1.68% |
+500,000
|
|
||
16
AstraZeneca
AZN
$302B
| $32.2M | 1.63% |
350,000
+50,000
|
|
||
17
Teva Pharmaceuticals
TEVA
$36.7B
| $31.2M | 1.58% |
+1,000,000
|
|
||
18
Penumbra
PEN
$13.2B
| $31.1M | 1.58% |
100,000
+50,000
|
|
||
19
Teleflex
TFX
$4.94B
| $30.5M | 1.55% |
+250,000
|
|
||
|
20
BrightSpring Health Services
BTSG
$8B
| $28.1M | 1.42% |
750,000
-400,000
|
|
||
21
Edwards Lifesciences
EW
$49.8B
| $27.7M | 1.4% |
325,000
+125,000
|
|
||
22
Mineralys Therapeutics
MLYS
$2.25B
| $27.2M | 1.38% |
750,000
-750,000
|
|
||
23
Centene
CNC
$17.9B
| $26.7M | 1.36% |
650,000
+250,000
|
|
||
24
Cooper Companies
COO
$14.5B
| $26.6M | 1.35% |
325,000
+230,000
|
|
||
25
Merck
MRK
$289B
| $26.3M | 1.33% |
+250,000
|
|